IL6R D358 SNP A/A is associated with increased 28-day in-hospital mortality in the primary cohort. (A) Forest plot of multivariable analysis within Massachusetts General Brigham (MGB) cohort (adj P value, adjusted P value). (B) Cumulative 28-day mortality among patients with IL6R D/D, D/A, and A/A in the MGB cohort. (C) Distribution of genes mutated in patients found to have CHIP with a VAF of 0.02 or greater in the tocilizumab cohort. (D) Comparison of mutant VAF between day 1 and late timepoint in serial samples from the tocilizumab cohort (see supplemental Figure 5).